Prevalence and outcomes of Covid-19 in Parkinson's disease: Acute settings and hospital

Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: A multicentre UK-based study

“…Our study showed an overall 34-day mortality rate of 38.4% which is in line with data deriving from other US and European cohorts of hospitalised PD patients with COVID-19 of 35.8% and 35.4%, respectively [ 13 , 55 ]. These mortality rates appear to be higher compared with data from the general population with COVID-19 hospitalised over the same period (overall mortality rate of 25%) [ 56 ], adding to the evidence that PwP have a significant risk of poor outcomes [ 6 ]. Risk factors for increased mortality in our study were increased age, male sex and diagnosis of PD dementia while protective factors were low CFS (<5), being vaccinated, and COVID-19 with no or mild respiratory symptoms, in agreement with the literature on the general population and PD patients [ 4 , 13 , 21 ].…”

“…Advanced age, frailty and impaired cough reflex are commonly observed in people with PD (PwP) and might contribute to their susceptibility to developing severe acute respiratory syndrome [5]. A variety of studies have investigated mortality in PwP and COVID-19 with figures ranging from 5% to 100% [6]; the wide range reflects the heterogeneity of methodologies used (case report, series, surveys, retrospective or prospective cohort studies) and cohort analysed (home-based vs hospitalised patients, early vs advanced patients, etc.) [7][8][9][10][11][12][13][14][15][16][17][18][19].…”

“…[7][8][9][10][11][12][13][14][15][16][17][18][19]. However, whether the factors associated with the significant high risk of death from COVID-19 in PwP are related to PD or to other concomitant and known risk factors such as comorbidities (hypertension, diabetes, pulmonary disease, obesity, immunosuppression, and dementia), older age (>60 years) and frailty remains unclear [6]. Participants in the COVID-19 PD UK study include inpatients with PD and related neurodegenerative diseases (atypical parkinsonian syndromes (APS) including multiple system atrophy (MSA), progressive supranuclear palsy (PSP), as well as dementia with Lewy bodies (DLB)).…”

“…compared to 12(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)), those in wave two compared to wave one(15 (6-27) and 12(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19), respectively) and those with delirium (15 (7-29) compared to 12 (6-21)). Time until discharge for further patient, COVID-19 and PD characteristics are detailed in S2 Table.…”

Vaccination Against SARS-Cov-2 among Patients with Parkinson’s Disease Based on the Results of COVPARK-LT Study

“…Data on the mortal ity from COVID-19 in PD are con tro ver sial: Zhang et al (2020) com pared 78,355 non-PD COVID-19 pa tients with 694 COVID-19 pa tients with PD and found an in creased mor tal ity even af ter ad just ing and match ing for age and sex [3]; a sys tem atic re view by Artusi et al (2021) on a to tal of 1061 PD pa tients with con firmed COVID-19 showed a higher hos pi tal iza tion rate, case fa tal ity and mor tal ity [3]; a multicenter Ger man study by Scherbaum et al (2021) showed that the prev a lence and mor tal ity of COVID-19 was higher in PD than in non-PD in-pa tients [3]; an increase of PD long-term mor tal ity was de ter mined by Fedeli et al (2022) [4]. A de tailed re view by Fearon et al (2021) led to con clu sion that COVID-19 mor tal ity is proba bly not in creased in PD pa tients [5]. The Co lum bia Univer sity Med i cal Cen ter co hort study (Xu et al, 2022) [6] and the Lom bardy com mu nity-based case-con trol study (Fasano et al, 2021) did not find suf fi cient ev i dence that PD is an in de pend ent risk fac tor for se vere COVID-19 and death [7].…”